Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1799 1
1823 1
1842 1
1858 1
1874 1
1875 1
1876 1
1880 2
1882 3
1883 2
1888 2
1891 1
1893 1
1896 2
1897 1
1898 3
1899 6
1900 5
1901 4
1902 2
1903 4
1904 1
1905 8
1906 1
1907 8
1908 5
1909 5
1910 15
1911 10
1912 7
1913 10
1914 20
1915 15
1916 13
1917 27
1918 23
1919 13
1920 23
1921 20
1922 16
1923 18
1924 25
1925 15
1926 21
1927 38
1928 25
1929 20
1930 36
1931 39
1932 26
1933 26
1934 27
1935 29
1936 39
1937 35
1938 31
1939 32
1940 22
1941 28
1942 25
1943 27
1944 32
1945 261
1946 502
1947 1128
1948 1553
1949 1187
1950 1428
1951 1856
1952 1823
1953 1998
1954 1925
1955 1859
1956 1728
1957 1778
1958 1865
1959 1078
1960 378
1961 528
1962 522
1963 632
1964 873
1965 1688
1966 2678
1967 2962
1968 3371
1969 3565
1970 3728
1971 3843
1972 3868
1973 4024
1974 4003
1975 5329
1976 5299
1977 5495
1978 5333
1979 6012
1980 5973
1981 6629
1982 6962
1983 7842
1984 8569
1985 8576
1986 8707
1987 9394
1988 10047
1989 12298
1990 12648
1991 13282
1992 13806
1993 14285
1994 14572
1995 15394
1996 15930
1997 17080
1998 17798
1999 18173
2000 19421
2001 20088
2002 20615
2003 22471
2004 23421
2005 25606
2006 28059
2007 29610
2008 31254
2009 33407
2010 36228
2011 40046
2012 42996
2013 44481
2014 45844
2015 46667
2016 47143
2017 47789
2018 48502
2019 50832
2020 69896
2021 85917
2022 84025
2023 73316
2024 66943
2025 68857
2026 44787
2027 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,389,902 results

Results by year

Citations

2 articles found by citation matching
A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.
[No authors listed] Gastroenterol Hepatol (N Y). 2017. PMID: 29950953 Free PMC article. No abstract available.
Show all

Search results

Filters applied: . Clear all
Page 1
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Zeuzem S, et al. N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417. N Engl J Med. 2018. PMID: 29365309 Free article. Clinical Trial.
METHODS: We conducted two phase 3, randomized, open-label, multicenter trials. Patients with genotype 1 infection were randomly assigned in a 1:1 ratio to receive once-daily glecaprevir-pibrentasvir for either 8 or …
METHODS: We conducted two phase 3, randomized, open-label, multicenter trials. Patients with genotype 1 infection …
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.
Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, Kwo PY, Weiland O, Villa E, Heo J, Gane E, Ryder SD, Welzel TM, Ruane PJ, Agarwal K, Ng TI, Xue Z, Lovell SS, Krishnan P, Kopecky-Bromberg S, Trinh R, Mensa FJ, Wyles DL. Flamm S, et al. J Viral Hepat. 2019 Mar;26(3):337-349. doi: 10.1111/jvh.13038. Epub 2018 Dec 11. J Viral Hepat. 2019. PMID: 30421537 Free PMC article. Clinical Trial.
Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patien …
Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficac …
Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial.
Haukoos J, Rothman RE, Galbraith JW, Hopkins E, Hsieh YH, Lyle C, Gravitz S, Kamis KF, White DAE, Lyons MS, Gardner EM, Al-Tayyib AA, Sabel AL, Linas BP, Morgan JR, Wyles DL, Rowan SE; DETECT Hep C Screening Trial Investigators. Haukoos J, et al. JAMA. 2025 Aug 12;334(6):497-507. doi: 10.1001/jama.2025.10563. JAMA. 2025. PMID: 40632510 Free PMC article. Clinical Trial.
Compared with targeted HCV screening, nontargeted HCV screening identified significantly more new diagnoses of HCV infection (RR, 1.34 [95% CI, 1.05-1.70]; P = .02). Among patients newly diagnosed with HCV infection, …
Compared with targeted HCV screening, nontargeted HCV screening identified significantly more new diagnoses of HCV i …
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Asselah T, et al. Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22. Clin Gastroenterol Hepatol. 2018. PMID: 28951228 Clinical Trial.
In all studies the primary endpoint was sustained virologic response at 12 weeks after treatment (SVR12) in the intention-to-treat population. RESULTS: Among patients receiving glecaprevir/pibrentasvir for 8 weeks, rates of SVR12 were 98% …
In all studies the primary endpoint was sustained virologic response at 12 weeks after treatment (SVR12) in the intention-to-t …
Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Brown RS Jr, et al. J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2. J Hepatol. 2020. PMID: 31682879 Free article. Clinical Trial.
BACKGROUND & AIMS: Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1-6 in treatment-naive patients without cirrhosis. We evaluated …
BACKGROUND & AIMS: Eight-week glecaprevir/pibrentasvir leads to high rates of sustained virological response at post-treat …
[HCV].
Tsujii H, Yoshikawa M, Nakano H. Tsujii H, et al. Rinsho Byori. 1993 Nov;41(11):1232-9. Rinsho Byori. 1993. PMID: 8283800 Japanese.
Genotypes of HCV can be classified into at least six basic groups, genotype I-IV can be distinguished by RT-PCR with type-specific primers. We report here that the prevalence of type-I, II, III, IV, and mixed type (II + IV) are 1.0%, 90.3%, 3 …
Genotypes of HCV can be classified into at least six basic groups, genotype I-IV can be distinguished by RT-PCR with ty …
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Forns X, et al. Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14. Lancet Infect Dis. 2017. PMID: 28818546 Clinical Trial.
BACKGROUND: The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies. We aimed to assess the efficacy and safety of 12 …
BACKGROUND: The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has s …
Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
Aghemo A, Persico M, D'Ambrosio R, Andreoni M, Villa E, Bhagat A, Gallinaro V, Gualberti G, Merolla RCD, Gasbarrini A. Aghemo A, et al. PLoS One. 2023 Feb 2;18(2):e0280165. doi: 10.1371/journal.pone.0280165. eCollection 2023. PLoS One. 2023. PMID: 36730135 Free PMC article.
INTRODUCTION: Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naive (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis …
INTRODUCTION: Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttrea …
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, Zhang M, Kim YJ, Lim SG, Fredrick LM, Lu W, Liu W, Kalluri HV, Krishnan P, Tripathi R, Mobashery N, Burroughs M, Asatryan A, Jia J, Hou J. Wei L, et al. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16. Lancet Gastroenterol Hepatol. 2020. PMID: 32682494 Clinical Trial.
BACKGROUND: Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. ...Upper respiratory tract infection was the most common adverse …
BACKGROUND: Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatiti …
Advances in the treatment of HIV/HCV coinfection in adults.
Schlabe S, Rockstroh JK. Schlabe S, et al. Expert Opin Pharmacother. 2018 Jan;19(1):49-64. doi: 10.1080/14656566.2017.1419185. Expert Opin Pharmacother. 2018. PMID: 29252031 Review.
INTRODUCTION: Direct-acting antivirals (DAA) have revolutionized the modern treatment of chronic hepatitis C (HCV). These highly efficacious, well-tolerated, all-oral HCV regimens allow cure of HCV in over 95% of HCV-monoinfected as well as HIV/HCV …
INTRODUCTION: Direct-acting antivirals (DAA) have revolutionized the modern treatment of chronic hepatitis C (HCV). These highly effi …
1,389,902 results
You have reached the last available page of results. Please see the User Guide for more information.